



# ANNUAL REPORT

Fiscal Year 2020-2021





## A Letter from our Executive Director



When we began this year, we thought that COVID-19 would soon be a distant memory. Sadly, the year passed and COVID-19 is still with us, affecting us at work and at play. Yet, we are encouraged by the increases in vaccination rates in Los Angeles and the U.S. We are proud of our work as the Los Angeles site for the Moderna vaccine trial. We are especially proud of progress in health equity, with our Vine Street Clinic staff recruiting, enrolling and retaining significant numbers of participants from minority racial and ethnic backgrounds.

The work continues. With a grant from the California Community Foundation our CBAM team conducted formative work with community members, clinicians and stakeholders dedicated to ensuring access to vaccines for people living in South Los Angeles. Our report documents this work and calls out best practices to ensure equity in healthcare access to be fielded with the next pandemic, epidemic or health threat.

An achievement I am most proud of is the ability of CBAM faculty and staff members to do key COVID-19 vaccine research and conduct important research into treatments for diseases that affect those living with or at risk for HIV and for addictions. We made remarkable gains in scientific leadership in the networks of HPTN, CTN and HVTN. Our work was published in the highest impact journals in medicine – like New England Journal of Medicine and the LANCET. Our leadership is documented in specialty journals, too – like Drug and Alcohol Dependence, AIDS and Behavior, and Journal of Acquired Immunodeficiency Syndrome. We are leading the science that will change treatment at the intersection of HIV and addiction medicine toward “whole person care.”

I'll close by recognizing our broadened efforts to bring in new faculty of diverse backgrounds who share our goal of using research to bring cutting-edge tools in healthcare to communities that need these most. This was a banner year for mentorship, with several postdocs and fellows promoting to junior faculty members.

With all of these achievements, imagine what we will do in the next year...


A handwritten signature in black ink, appearing to read 'S. S. S.' or similar.



## Research Highlights



In pursuit of our mission, CBAM conducts research on medical, behavioral, and combination approaches to the prevention and treatment of chronic illnesses, with a particular focus on addiction and HIV. We stress the values of integrity and scientific rigor in the conduct of our research and work closely with the communities we serve to ensure that the best of care is given. The following pages highlight our research activities over the past year.



**COVID-19**  
Prevention Network



**CHIPTS**  
Center for HIV Identification, Prevention  
and Treatment Services



**HPTN**  
HIV Prevention  
Trials Network



**HIV VACCINE**  
TRIALS NETWORK





## New Studies

### INTEGRA Mobile Clinic Study

CBAM launched its first mobile clinic this year! The inaugural study using the mobile clinic is "INTEGRA: A Vanguard Study of Integrated Strategies for Linking Persons with Opioid Use Disorder to Care and Prevention for Addiction, HIV, HCV and Primary Care". This project was years in the making, conceived by our own Dr. Steve Shoptaw and Dr. Nabila El-Bassel of Columbia University and developed in collaboration with NIDA and the HIV Prevention Trials Network. Los Angeles is one of five sites nationally conducting this trial to determine whether provision of active navigation plus integrated services delivered in the mobile unit improves medication for opioid use disorder and HIV care and prevention outcomes over active navigation to existing services located in the community. Dr. David Goodman-Meza is the Investigator of Record for the UCLA site and leads the study team in Los Angeles.



Dr. David Goodman-Meza is the Investigator of Record for the UCLA site and leads the study team in Los Angeles.

### PrEP Uptake Intervention



Dr. Ron Brooks was awarded a grant from the National Institute of Mental Health entitled, "Evaluating the Feasibility and Acceptability of a Latino MSM Focused PrEP Uptake Intervention". The project is being carried out in collaboration with Bienestar Human Services and Friends Research Institute. While evidence indicates that PrEP use is rising in the U.S., disparities persist in uptake among Latino MSM, despite their reported high levels of interest in using PrEP. To address this disparity, Dr. Brooks is implementing project to develop a pilot PrEP intervention to facilitate initiation and adherence to PrEP among immigrant Latino MSM. If the intervention shows promise, the findings will support the preparation of a larger scale R01 efficacy trial.

### Alcohol Research

Under the leadership of Dr. Steven Shoptaw, Director of CBAM, and Dr. Lara Ray, head of the UCLA Addictions Lab, UCLA was awarded contract to become a clinical




National Institute on Alcohol Abuse and Alcoholism

research site for the NIAAA Medications Development Clinical Investigations Network for the Treatment of Alcohol Use Disorder. The purpose of this contract is to expedite discovery of promising new treatments for alcohol use disorder. Each clinical site shall provide a full range of services in support of the conduct of Phase I and Phase II clinical trials. The first trial is on the drawing boards and will be launched in the coming year.



## New Studies continued

Much of our work at CBAM is focused on methamphetamine (MA). MA is more prevalent than any other drug, including opioids, with 37 million users of MA and amphetamine worldwide and 1.4 million users in the U.S. in 2016. MA has been recognized as contributing substantially to the U.S. opioid crisis, with about half of MA poisoning deaths also caused by opioids. Additionally, MA leads to changes in sexual risk behavior, in adherence to biomedical prevention, in viral immunology, and in mucosal inflammation, all of which increase risk for HIV-1 transmission among MA-using men who have sex with men (MSM), their sexual partners, and their networks. The following studies were launched this year with a particular focus on MA.



### CMAX

Contingency Management (CM) is a behavioral modification tool built on principles of operant conditioning that incorporates concepts of delay discounting and risk minimization from behavioral economics to incentivize prosocial behaviors. In short, it uses monetary incentives as positive reinforcement for specific behaviors. However, the effects of CM on the behavioral and biological factors that promote HIV transmission in MSM networks have only been partially evaluated. The aim of the CMAX pilot study, led by Dr. Jesse Clark, is to assess the logistics, feasibility, and preliminary estimates of effect of contingency for adherence to HIV medication among MSM who use methamphetamine.

### Mirtazapine Safety Trial

There are no FDA-approved pharmacologic treatments for MA use disorder, a major gap in addiction medicine. This study builds on prior work at the University of California, San Francisco (UCSF) on the use of the medication Mirtazapine for the treatment of MA use disorder. This 2-site collaboration between UCSF and UCLA aims to further evaluate the safety of mirtazapine's use for this purpose, including for those who use MA and are also taking methadone. The study will enroll 24 participants across both UC sites, with the goal of moving into a larger-scale, efficacy trial soon after.

### Career Development Award

Dr. Michael Li received a career development award from the National Institute on Drug Abuse entitled, "Trajectories of socially regulated gene expression, methamphetamine use, and viral load among HIV-positive men who have sex with men (MSM) receiving contingency management". In addition to providing mentored training from interdisciplinary faculty in a combination of behavioral and basic sciences, this grant will enable Dr. Li to investigate whether a neutrally-regulated "stress" gene expression pattern can serve as a clinically meaningful, non-abstinence-based endpoint for contingency management for methamphetamine use disorder (MUD) in men who have sex with men (MSM) who are living with HIV.



## COVID-19 Prevention

While the focus of CBAM's work has been and continues to be the prevention and treatment of Addiction and HIV, COVID-19 was a once-in-a-century health crisis and the disproportionate impact it has on the communities we serve was evident from the beginning, leading us to take on the following projects.



### Moderna Vaccine Trial



Because of our previous work with the National Institute on Allergy and Infectious Disease through the HIV Vaccine Trials Network, we were approached to participate in the COVID-19 vaccine clinical trials. Under the leadership of Dr. Jesse Clark, our team at the UCLA Vine Street Clinic enrolled 194 participants into the Moderna trial in less than two months. Our staff took on extensive efforts to reach essential workers, people of color, and others at high risk for COVID to ensure adequate inclusion and representation. Early trial results show an efficacy rate of 94.1% and booster shots will be rolled out in the Fall of 2021.

### Targeted Community Education

CBAM partnered with the California Community Foundation to expand the inclusion of underserved populations in the broad scale implementation of COVID-19 vaccinations in Los Angeles County. Over the course of several months, we hosted a series of on-line conferences with providers, community leaders, and interested individuals from South LA. We gathered key input from the community and provided up-to-date information, best practices, and strategies for increasing vaccine access and uptake.



### California Science Center Exhibit



The California Science Center launched their COVID-19 exhibition in April, 2021. Our CBAM staff were key consultants in developing this important exhibition.

Our participation in the Moderna COVID Vaccine trial also garnered local attention with the following outlets featuring our team.





The Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) is a collaboration of leading researchers promoting collaborative research, networking, and capacity building among HIV researchers and communities in efforts to eliminate new HIV infections and health disparities among key populations.

Supplemental Funding



This year, CHIPTS was awarded two one-year grants by the National Institute of Mental Health totaling \$437,879 as part of the national [Ending the HIV Epidemic](#) initiative (EHE). Led by Dr. Ron Brooks, the first project studied the use of telehealth to optimize PrEP care continuum outcomes among cis Black & Latina Heterosexual Women.



Also funded, was the UCLA Rapid, Relevant, Rigorous Implementation Science Hub led by Dr. Alison Hamilton. The aims of the Hub are to provide implementation science training and ongoing coaching and technical assistance to EHE grantees; to accelerate HIV/AIDS research impacts by interfacing with and contributing to the national EHE Coordinating Center and identifying resources and opportunities for advancing evidence-based interventions through the implementation pipeline; and finally, to provide and promote a platform for multidisciplinary collaborations in support of HIV/AIDS-related implementation research.

Training Activities

CHIPTS continued its efforts to improve trust within the medical system. On July 29, 2020, the Center hosted a webinar on Gaining Patients' Trust in the Age of COVID-19, attended by more than 250 community providers, educators, and partners. A link to the webinar can be found [here](#). On August 29, 2020, the Center led a virtual training for providers on Addressing Medical Mistrust in Black Communities. The objectives of this training were to improve understanding of the historical foundations of medical mistrust in Black communities, to discuss clinic and system level changes that foster patient trust, and to provide attendees with skills and resources to interact with patients in a manner that encourages healthcare engagement and improves health outcomes.



CHIPTS awarded funding to young investigators for several pilot studies this year, including:

**New Pilot Studies**

<u>Investigator</u>	<u>Study Title</u>
Cherie Blair, MD	Joint effects of methamphetamine use, HIV, and sexually transmitted infections on systemic/mucosal inflammation and mucosal HIV shedding.
Erik Storholm, PhD	A Community-Level HIV Prevention for Young Black Men
Joshua Rusow, MSW	An exploration of the role of violence victimization, mental health, substance use, and HIV behaviors and decision-making

For more information on CHIPTS, visit the [website](#).



## Training, Evaluation & Capacity Building

CBAM is dedicated to training future researchers.

### NIDA Summer Intern

CBAM again participated in the National Institute on Drug Abuse Summer Research Internship Program, which supports undergraduate students with a focus on increasing underrepresented populations in addiction research. This year, David Bodden joined us remotely from the University of Kentucky where he is pursuing a Bachelor's degree in Public Health with a focus on Health, Society & Populations.

### Bridge Fellowship

This year our CBAM and CHIPTS leaders generated a new program to provide salary support and senior mentorship to three faculty members who are assistant professors from minority racial/ethnic backgrounds. The goal of this program is to provide access to data sets (to generate publications) and to support mentorship (to link with senior scientists and NIH program officers) as these faculty approach their 8 year limit reviews to Associate Professor.

## Media

Some of the biggest news out of CBAM this year, was coverage of our article on the New England Journal of Medicine, discussing a promising treatment for methamphetamine use disorder. This is an issue we have been working to address for more than 25 years and we are thrilled to see this get the attention it deserves.



It was also mentioned by the Director of the [National Institute on Drug Abuse](#), Dr. Nora Volkow, in one of her Fireside Chats.



And Dr. Steven Shoptaw was featured in the [HIV Prevention Trials Network](#) February 2021 Newsletter.



## Scientific Publications



As scientists, our biggest impact comes from the knowledge we generate and share. It's that knowledge of what works, what doesn't and why that leads to better policy, better medicine and better lives for those we serve. Highlights from this past year include:

- M.H. Trivedi, R. Walker, W. Ling, A. dela Cruz, G. Sharma, T. Carmody, U.E. Ghitza, A. Wahle, M. Kim, K. Shores-Wilson, S. Sparenborg, P. Coffin, J. Schmitz, K. Wiest, G. Bart, S.C. Sonne, S. Wakhlu, A.J. Rush, E.V. Nunes, and S. Shoptaw. **Bupropion and Naltrexone in Methamphetamine Use Disorder.** [The New England Journal of Medicine](#). 021;384:140-53.
- Mariah M. Kalmin, David Goodman-Meza, Erik Anderson, Ariana Abid, Melissa Speener, Hannah Snyder, Arianna Campbell, Aimee Moulin, Steve Shoptaw, Andrew A. Herring. **Voting with their feet: Social factors linked with treatment for opioid use disorder using same-day buprenorphine delivered in California hospitals.** [Drug and Alcohol Dependence](#). Vol 222, 1 May 2021, 108673.
- Passaro RC, Chávez-Gomez S, Castañeda-Huaripata A, Gonzales-Saavedra W, Beymer MR, Segura ER, Nanclares F, Dilley J, Cabello R, Clark JL. **Personalized Cognitive Counseling Reduces Drinking Expectancy Among Men Who Have Sex with Men and Transgender Women in Lima, Peru: A Pilot Randomized Controlled Trial.** [AIDS Behav](#). 2020 Nov;24(11):3205-3214.
- Nieto O, Brooks RA, Landrian A, Cabral A, Fehrenbacher AE. **PrEP discontinuation among Latino/a and Black MSM and transgender women: A need for PrEP support services.** [PLoS One](#). 2020 Nov 5;15(11):e0241340.
- Nabila El-Bassel, Steven Shoptaw, David Goodman-Meza, Hiromi Ono. **Addressing long overdue social and structural determinants of the opioid epidemic.** [Drug and Alcohol Dependence](#). Vol 222, 1 May 2021, 108679.
- Sae Takada, Pamina Gorbach, Ron Brookmeyer & Steven Shoptaw. **Associations of social capital resources and experiences of homophobia with HIV transmission risk behavior and HIV care continuum among men who have sex with men in Los Angeles.** [AIDS CARE](#). Volume 33, 2021 - Issue 5.

To learn more and to read summaries of each article, visit our [website](#).



CENTER FOR BEHAVIORAL & ADDICTION MEDICINE  
 Financial Statement for Fiscal Year 2019/2020  
 (July 1, 2020 through June 30, 2021)

INCOME	<u>Permanently</u>	<u>Temporarily</u>	Unrestricted	Total	FY 2019/2020
	<u>Restricted</u>	<u>Restricted</u>			
Federal Contracts & Grants	\$ 8,724,054	\$ -	\$ -	\$ 8,724,054	\$ 5,632,007
State/Local Contracts & Grants	\$ -	\$ -	\$ -	\$ -	\$ 9,162
Subcontracts	\$ 1,011,357	\$ -	\$ -	\$ 1,011,357	\$ 900,000
Corporations		\$ -	\$ -	\$ -	\$ 30,000
Foundations	\$ 170,000	\$ -	\$ -	\$ 170,000	\$ -
Individuals	\$ -	\$ -	\$ -	\$ -	\$ 4,543
UC Funds	\$ 195,946	\$ -	\$ -	\$ 195,946	\$ 84,460
Clinical Services Income	\$ -	\$ 248,647	\$ -	\$ 248,647	\$ 198,919
<b>TOTAL INCOME</b>	<b>\$ 10,101,357</b>	<b>\$ 248,647</b>	<b>\$ -</b>	<b>\$ 10,350,004</b>	<b>\$ 6,859,090</b>
<b>EXPENSES</b>					
Academic Salaries				\$ 526,249	\$ 438,225
Staff Salaries				\$ 1,899,712	\$ 1,546,299
Fringe Benefits				\$ 878,737	\$ 850,229
Stipends - Postdoctoral Fellows				\$ -	\$ 6,942
Stipends - Interns				\$ 2,400	\$ 6,840
Consultants/Guest Lecturers				\$ 129,788	\$ 11,372
Employee Training/Certifications/Licenses/Memberships				\$ 2,975	\$ 3,985
Subawards				\$ 259,950	\$ 192,705
Funds Transferred to Other Departments (Direct)				\$ 963,309	\$ 782,957
Space Rental				\$ 183,980	\$ 173,351
Alterations/Renovations				\$ 119,547	\$ 107
Communications				\$ 56,383	\$ 62,145
Clinic Operations				\$ 70,852	\$ 30,167
Vehicle Purchase				\$ 33,961	\$ -
Vehicle Operating Costs				\$ 11,843	\$ -
General Supplies & Equipment				\$ 8,785	\$ 3,007
Computers, Software & Computer Supplies				\$ 32,413	\$ 12,976
Medical Supplies				\$ 31,362	\$ 20,127
Project-Related Supplies				\$ 61,367	\$ 31,041
Travel and Events				\$ 7,003	\$ 108,997
Postage/Courier				\$ 13,369	\$ 26,666
Print/Copy Services				\$ 5,976	\$ 6,363
Publication Fees				\$ 15,610	\$ 15,000
Transcription Services				\$ 5,410	\$ 1,357
Recruitment Ads				\$ 17,034	\$ 70,468
Lab Services				\$ 47,065	\$ 100,039
Pharmacy				\$ 15,663	\$ 31,644
Inpatient Care				\$ 4,177	\$ 153,397
Participant Incentives				\$ 263,149	\$ 86,027
Website Services				\$ -	\$ 3,758
Miscellaneous				\$ 5,236	\$ 1,726
Indirect Charges				\$ 1,353,402	\$ 1,265,743
<b>TOTAL EXPENSES</b>				<b>\$ 7,026,704</b>	<b>\$ 6,043,659</b>
<b>NET INCOME (LOSS) YTD*</b>				<b>\$ 3,323,300</b>	<b>\$ 815,431</b>

*This document was generated internally. It is not an audited financial statement.*

*\*The net balance is primarily restricted project funding that will carryover into the next fiscal year. We will carry over a larger balance than usual due to COVID-related delays.*



## About CBAM

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illness, especially in communities with health disparities.

CBAM works at the intersection of academia and community with a focus on treating addiction and preventing the spread of HIV. We are housed in the UCLA Department of Family Medicine. Our faculty include:



**Steven Shoptaw, PhD**

Executive Director, UCLA Center for Behavioral & Addiction Medicine  
PI/Director, UCLA Center for HIV Identification, Prevention & Treatment Services  
Professor and Vice Chair of Research, UCLA Dept. of Family Medicine  
Professor, Department of Psychiatry and Biobehavioral Sciences



**Jesse Clark, MD, MSc**

Associate Professor in Residence, UCLA Dept. of Medicine, Division of Infectious Disease  
Associate Professor in Residence, UCLA Dept. of Family Medicine  
UCLA Vine Street Clinic Medical Director  
Director, South American Program in HIV Prevention Research (SAPHIR)



**Oladunni Adeyiga, MD**

Assistant Clinical Professor, UCLA Dept. of Medicine, Division of Infectious Disease



**Ron Brooks, PhD**

Assistant Professor, UCLA Department of Family Medicine



**David Goodman-Meza, MD, MAS**

Assistant Clinical Professor, UCLA Dept. of Medicine, Division of Infectious Disease



**Timothy Hall, MD, PhD, FAPA FASAM**

Assistant Clinical Professor, UCLA Department of Family Medicine



**Mariah Kalmin, PhD**

Assistant Professor, UCLA Department of Family Medicine



**Michael Li, PhD**

Assistant Professor, UCLA Department of Family Medicine




**Dilara Uskup, PhD**

Assistant Professor, UCLA Department of Family Medicine



## Show your support!

To help support this life-changing work, visit us at <http://www.uclacbam.org/about-us/donate/> or call (310) 794-0645 to speak with our Administrative Director. More than 92% of every donation goes directly to serve our mission and all donations are tax deductible. Naming opportunities are available!



## Contact Us!

UCLA Center for Behavioral &  
Addiction Medicine  
10880 Wilshire Blvd., Ste. 1800  
Los Angeles, CA 90024  
(310) 794-0619  
[cbam@mednet.ucla.edu](mailto:cbam@mednet.ucla.edu)  
[cbam.ucla.edu](http://cbam.ucla.edu)